Tuesday 14 April 2026

Pharma & Biotech Start-up & Scale-up News

Featured

Revolution Medicines
A clinical-stage precision oncology company focused on discovering, developing and delivering novel targeted therapies for patients with RAS-addicted cancers.
Biotechnology
Biocytogen inks antibody deal with BeOne, expanding strategic ties
10 July 2025
article
IDEAYA exercises option for license on Biocytogen’s IDE034
11 November 2024

Latest Ones To Watch News

Pharmaceutical
Travere’s Filspari wins landmark US approval
14 April 2026
Biotechnology
Adcendo completes $75 million Series C financing
14 April 2026
Biotechnology
SynOx Therapeutics heading for FDA filing for emactuzumab in TGCT
14 April 2026
More ones to watch news >
Reset all filters
Refine search
Travere Therapeutics
Travere Therapeutics
OriCell Therapeutics
OriCell Therapeutics
Annovis Bio
Cue Biopharma
Soleno Therapeutics
MoonLake Immunotherapeutics
Excellergy
Terns Pharmaceuticals
Karyopharm Therapeutics
Rhythm Pharmaceuticals
Ovid Therapeutics
Alto Neuroscience
Purple Biotech
BeOne Medicines
Medicus Pharma
Antengene
Priovant Therapeutics
Abcuro
Protara Therapeutics
Ocular Therapeutix


Today's issue

CrossBridge Bio latest ADC firm to be snapped up in Lilly deal
Biotechnology
CrossBridge Bio latest ADC firm to be snapped up in Lilly deal
14 April 2026
Biotechnology
FDA draft guidance on genome editing safety standards
14 April 2026
Pharmaceutical
MHRA approves new high dose regimen of Spinraza
14 April 2026
Biotechnology
Positive Phase III results for Jaypirca in new CLL group
14 April 2026
Pharmaceutical
Travere’s Filspari wins landmark US approval
14 April 2026
Biotechnology
Adcendo completes $75 million Series C financing
14 April 2026
Biotechnology
SynOx Therapeutics heading for FDA filing for emactuzumab in TGCT
14 April 2026


Company Spotlight

A clinical-stage precision oncology company focused on discovering, developing and delivering novel targeted therapies for patients with RAS-addicted cancers.




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze